Adult Stem Cell Technology Platforms

Since the 1980’s researchers at CTIBIOTECH have always been at the forefront of what is now called Regenerative Medicine. Experts in harvesting, manipulation, differentiation and development of human tissues from stem cell and progenitor cell tissues, they have published widely in this field, been involved in clinical trials and patented commercially available work.

Stem cells can be harvested from the following sources:

The founders of CTIBIOTECH, Colin McGuckin and Nico Forraz were the first in the world to create liver-like tissue from adult stem cells, using umbilical cord blood as the source of stem cells. They have also produced many different tissue types from adult and neonatal cell sources including:

From the initial source CTIBIOTECH has experience of:

Collection of samples at sterile grade

---

CTIBIOTECH has developed specific systems for stem cell harvesting from different tissue sources. We have also assisted both academic and company groups to develop, refine, patent, CE mark and FDA-approve several stem cell harvesting systems.

An example of this can be found here

Processing of tissues is an essential element in the production of viable and usable stem cells without contamination and unnecessary stimulation of the cells.

Processing of physical tissue is different from processing fluidic tissue (Eg., peripheral blood) and requires processes without heat or trauma to the tissue.

---

Such characterisation has allowed development of highly sophisticated techniques to harvest extremely rare cell populations such as the Cord Blood-derived Embryonic-like Cells (CBE)

---

---

Cellular interactions between different cell types can therefore be controlled.

CTIBIOTECH staff have designed, created and implemented several GMP cell bioprocessing centres in both the academic and commercial sectors. These GMP centres have been used for both research and human clinical therapies.